Outpatient diagnostic imaging solutions company DeepHealth, Inc., a subsidiary of RadNet, Inc. (NASDAQ:RDNT), announced on Friday that it has received expanded FDA 510(k) clearance for its SmartMammo Dx AI software, now compatible with GE HealthCare's Senographe Pristina mammography systems.
Initially cleared in May 2012 for HOLOGIC mammography systems, SmartMammo Dx has been proven effective in patients with unilateral breasts and implants. This expanded clearance broadens DeepHealth's mission to improve breast cancer screening by increasing system compatibility.
SmartMammo Dx, a core component of the SmartMammo1 solution, enhances radiologists' ability to interpret digital breast tomosynthesis (DBT) mammograms with greater accuracy. It identifies suspicious lesions and calcifications while providing detailed case-specific suspicion levels. DeepHealth's technologies have supported millions of exams in the past two years through the Enhanced Breast Cancer Detection (EBCD) program at RadNet.
This expanded clearance is expected to drive broader adoption of AI-powered breast cancer screening, benefiting both RadNet and external providers. It also highlights the collaboration between DeepHealth and GE HealthCare to advance patient-centric, scalable imaging solutions.
FDA grants priority review to Innoviva's zoliflodacin for treatment of gonorrhea
AB Science secures Canadian patent for AB8939, completing global IP coverage for AML treatment
US FDA approves expanded indication for AbbVie's MAVYRET (glecaprevir/pibrentasvir) in acute HCV
Creo Medical secures FDA clearance for SpydrBlade Flex in US market
Psilera collaborates with Hesperos for PSIL-006 preclinical modelling for frontotemporal dementia
Myosin Therapeutics' MT-125 cleared by US FDA to initiate first-in-human trial in glioblastoma
Ondine's Steriwave proven effective against deadly Mucor fungus
AB Science receives EMA approval to extend Masivet shelf life to four years
Hemispherian's GLIX1 receives positive EU opinion for orphan designation in glioma
Arvinas and Pfizer submit FDA application for vepdegestrant in ESR1-mutated breast cancer
NRx Pharmaceuticals files ANDA for preservative-free IV ketamine
Innovent's IBI363 granted second breakthrough therapy designation in China
Implantica reports positive NICE guidance for RefluxStop procedure in UK hospitals